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146Early Tumor-Infiltrating Dendritic Cells
Change their Characteristics Drastically
in Association with Murine Melanoma
Progression
Takeshi Nakahara1,2, Junna Oba2, Chie Shimomura2, Makiko Kido-Nakahara2 and Masutaka Furue1,2Dendritic cells (DCs) have a critical effect on the outcome of adaptive immune responses against growing
tumors. Tumor-infiltrating dendritic cells (TIDCs) play diverse roles in the regulation of tumor regression or
growth, but the characteristics that distinguish those effects are obscure. In this study, we investigated the
frequency, phenotype, and function of TIDCs over time from early stages of melanoma growth in mice. Flow
cytometric analysis revealed that the tumors were infiltrated by a significant population of CD11cþ major
histocompatibility complex IIþ DCs, especially at an early stage of tumor growth. The allogeneic stimulatory
capacity of TIDCs increased with tumor growth, whereas this capacity of DCs in lymph nodes decreased. TIDCs
harvested at an early stage of melanoma (early TIDCs) accelerated tumor growth, but those harvested at a late
stage (late TIDCs) delayed tumor progression when they were coinjected with melanoma cells. Furthermore,
coinjection of early TIDCs failed to induce full immunocompetent maturation of CD8þ T cells, with much lower
expression of IFN-g, granzyme B, and perforin within the tumor microenvironment. In conclusion, TIDCs
change their characteristics from an immunoinhibitory to an immunostimulatory phenotype over time in as-
sociation with tumor progression.
Journal of Investigative Dermatology (2016) 136, 146-153; doi:10.1038/JID.2015.359INTRODUCTION
Dendritic cells (DCs) are potent antigen-presenting cells that
play key roles in initiating and regulating adaptive immune
responses against growing tumors (Liu and Nussenzweig,
2010; Steinman and Idoyaga, 2010). Although it is gener-
ally assumed that the presence of phenotypically mature DCs
in a tumor should promote protective antitumor immunity,
evidence to the contrary has been obtained (Jensen et al.,
2012; Sandel et al., 2005). To escape from antitumor im-
mune responses that DCs orchestrate, tumors have equipped
various mechanisms to impair the immunostimulatory func-
tions of DCs or even to manage them to promote tumor
growth and progression (Engelhardt et al., 2012; Gottfried
et al., 2006). The development of melanoma models in
mice has greatly contributed to the molecular understanding
of melanoma immunobiology, but the precise nature and
molecular mechanisms of tumor-infiltrating DCs (TIDCs)
have not been elucidated, and there is surprisingly little
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2012). One of the reasons for this might be that few studies
have aimed to elucidate the nature of TIDCs infiltrating early
stages of melanoma growth and their functional changes over
time. Thus, in this study, we performed quantitative, pheno-
typic, and functional analyses of TIDCs obtained from early
to late stages of murine melanoma cells inoculated with
Matrigel.
RESULTS
Murine melanomas are infiltrated by a significant population
of DCs, especially at an early stage of tumor growth
To investigate the intratumor dynamics of DCs, we first
examined the precise proportion and number of TIDCs dur-
ing tumor growth after melanoma inoculation. We began our
analysis 2 days after tumor inoculation, using tumors injected
intradermally with Matrigel, to develop a more complete
understanding of the characteristics of TIDCs from the early
tumor microenvironment. Mice were assessed for the pro-
portions and numbers of TIDCs over time after tumor injec-
tion (Figure 1a). Although tumors are first macroscopically
visible at about days 10e14 in the usual model, we could see
tumors and harvest them even at an early stage of tumor
growth using this Matrigel method (Figure 1b, Supplementary
Figure S1 online). In murine melanoma, TIDCs are identified
by their high expression levels of CD11c and major histo-
compatibility complex (MHC) class II (Figure 1c). As shown
in Figure 1d, flow cytometric analysis of tumor-infiltrating
cells revealed that the tumors were infiltrated by a signifi-
cant population of CD11cþ MHC IIþ DCs, especially at early
stages of tumor growth. TIDCs infiltration constituteduthors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
Figure 1. Murine melanomas are infiltrated by a significant population of
TIDCs. (a) B16 cells were suspended in Matrigel and inoculated into the
flanks of C57B/6 mice. After harvesting of tumors, tumor-infiltrating CD45þ
cells were isolated by density gradient centrifugation and were assessed for
the proportion and number of TIDCs by FACS. (b) Representative images of
melanoma are shown from mice 2 days or 11 days after tumor inoculation. (c)
TIDCs in melanoma stained for CD11c and MHC class II. (d) Time course of
the proportion and total number of TIDCs (CD11cþ/MHC class IIþ) in tumor-
infiltrating cells during melanoma growth. All values represent the mean  SE
of 3 to 12 mice. Representative data from three separate experiments are
shown. MHC, major histocompatibility complex; TIDCs, tumor-infiltrating
dendritic cells.
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harvested from the tumor at day 2. The proportion of TIDCs
increased until day 4 and then gradually decreased until day
14. On the other hand, the absolute number of TIDCs
increased over the course of tumor growth. In contrast with
the proportion of TIDCs, that of CD8þ T cells kept increasing
during tumor growth, resulted in the increase of the ratio of
CD8þ T cells to TIDCs (Supplementary Figure S2 online).
TIDCs are phenotypically more mature than DCs in draining
lymph nodes (LNs) during tumor growth
In subcutaneous LNs, migratory DCs are skin-derived DCs
and have a CD11cint MHC class IIhigh phenotype, whereas
resident DCs (rDCs) have a CD11chigh MHC class IIint
phenotype (Figure 2a) (Nakahara et al., 2010). Compared
with the dynamic change in the proportion of TIDCs, the
proportion of DCs in draining or nondraining LNs did notchange significantly during tumor growth (Figure 2b). There-
fore, the dynamic change of TIDCswasmuchmore prominent
than that of DCs in LNs. Next, we examined the phenotypic
maturation status of rDCs in draining LNs and TIDCs. rDCs in
draining LNs expressed somewhat higher levels of CD86 than
rDCs of naive control mice from days 2 to 8 after tumor
inoculation. After day 10, the expression of CD86 by rDCs in
draining LNs decreased to the level of rDCs of naive control
mice. Meanwhile, TIDCs expressed persistently higher levels
of CD86 than rDCs of naive control mice during tumor growth
(Figure 2c). Notably, TIDCs were phenotypically more mature
than rDCs in draining LNs at each time point, especially at
later time points of tumor growth (Figure 2d). These results
reveal that TIDCs are likely to be more active participants in
our melanoma model than rDCs in LNs.
TIDCs become more potent immunostimulatory DCs during
tumor growth
We next examined the immunostimulatory function of TIDCs
and DCs from draining LNs by measuring the proliferation of
allogeneic T cells in mixed lymphocyte reaction at early
(day 4) and late (day 11) time points of tumor growth. At
day 4, there was little difference in allogeneic stimulatory
capacity between TIDCs and DCs from draining LNs. On the
other hand, TIDCs had a more potent allogeneic stimulatory
capacity than DCs from draining LNs at day 11 (Figure 3a).
These results indicated that TIDCs increased their allogeneic
stimulatory capacity with time during melanoma growth,
whereas that was not the case for DCs from draining LNs. In
fact, late TIDCs had a more potent allogeneic stimulatory
capacity than early DCs when they were compared directly
(Figure 3b). In subsequent experiments, we used these early
(day 4) and late (day 11) TIDCs.
Early TIDCs express abundant immunoinhibitory molecules
Although it was once thought that phenotypically mature
DCs exclusively promote T-cell activation, this paradigm has
been challenged by the discovery of immunoinhibitory
molecules (Reis e Sousa, 2006). Although the CD86 expres-
sion levels of early and late TIDCs were similar, early TIDCs
were less immunostimulatory than their later counterparts.
Therefore, we next evaluated the expression of vascular
endothelial growth factor receptor 2 (VEGFR-2) and pro-
grammed death-ligand 1 (PD-L1), both of which are repre-
sentative immunoinhibitory molecules (Dikov et al., 2005;
Krempski et al., 2011; Mimura et al., 2007). As shown in
Figure 4a, early TIDCs expressed much higher levels of
VEGFR-2 and PD-L1 than rDCs from draining LNs. Although
late TIDCs also expressed higher levels of VEGFR-2 and PD-
L1 than rDCs from draining LNs, their expression levels were
significantly lower than those of early TIDCs. Actually, early
TIDCs expressed higher levels of VEGFR-2 and PD-L1 than
late TIDCs when they were compared directly (Figure 4b).
We also examined the expression levels of some other
immunoinhibitory genes such as indoleamine 2,3-
dioxygenase 1, indoleamine 2,3-dioxygenase 2, forkhead
box O3, signal transducer and activator of transcription 3,
and heme oxygenase-1, which are known to be associated
with immunosuppressive functions of DCs (Moreau et al.,
2009; Tran Janco et al., 2015). Interestingly, early TIDCs
expressed higher levels of such kinds of immunoinhibitorywww.jidonline.org 147
Figure 2. Phenotypic maturation
status of TIDCs or DCs in LNs during
melanoma growth (a) Subsets of DCs
in subcutaneous LNs of naive mice.
(b) Draining LNs (inguinal LNs, the
same side as tumor inoculation) or
nondraining LNs (inguinal LNs, the
opposite side from tumor inoculation)
were assessed for the number and
proportion of sDCs and rDCs. (c)
Expression of CD86 on TIDCs (green
lines) or rDCs from draining LNs of
tumor-bearing mice (red line) during
melanoma growth. rDCs from LNs of
naive control mice (gray line) were
used as a control. (d) Mean
fluorescence intensity (MFI) of CD86
expression on TIDCs or rDCs in
draining LNs was also assessed. All
values represent the mean  SE of 3 to
12 mice. Representative data from
three separate experiments are shown.
DCs, dendritic cells; LNs, lymph
nodes; rDCs, resident DCs; sDCs,
skin-derived DCs; TIDCs, tumor-
infiltrating dendritic cells.
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148genes than late TIDCs did (Figure 4c). These results may
explain why early TIDCs exhibit a less potent immunosti-
mulatory function than late TIDCs. In addition, these results
suggested that early TIDCs changed their characteristics from
an immunoinhibitory to an immunostimulatory phenotype
over time. We then investigated whether early TIDCs or late
TIDCs could promote or inhibit melanoma growth in vivo.Figure 3. Immunostimulatory
capacity of TIDCs and DCs from
draining LNs at different time points
of tumor growth. (a) CD11cþ DCs
from tumor, draining LNs, or LNs of
naive mice were sorted using anti-
CD11c magnetic-activated cell sorting
(MACS) beads 4 or 11 days after tumor
inoculation. Graded doses of DCs
were cocultured with allogeneic T
cells from Balb/c mice for 4 days. The
proliferation of allogeneic T cells was
assessed. (b) B16 cells were
inoculated into the C57B/6 mice at
day -4 or day -11. At day 0, TIDCs
were sorted and cocultured with
allogeneic T cells in the same setting.
All values represent the mean  SE of
3 to 12 mice. Representative data from
three separate experiments are shown
(*P < 0.05). DCs, dendritic cells; LNs,
lymph nodes; TIDCs, tumor-
infiltrating dendritic cells.
Journal of Investigative Dermatology (2016), Volume 136Early TIDCs accelerate tumor growth, whereas late TIDCs
inhibit it in vivo
To evaluate the role of TIDCs in tumor growth in vivo, early
or late TIDCs were mixed with melanoma cells, and were
coinjected intradermally. As expected, simultaneous inocu-
lation of early TIDCs significantly accelerated melanoma
growth, whereas late TIDCs inhibited it (Figure 5a). These
Figure 4. The expression of immunoinhibitory molecules on TIDCs decreases during tumor growth. (a) Representative histograms of VEGFR-2 and PD-L1
expression on TIDCs (green lines), rDCs from draining LNs (red lines), or rDCs from naive control mice (gray lines) 4 or 11 days after tumor inoculation. (b) MFI
of VEGFR-2 and PD-L1 on TIDCs or rDCs in draining LNs at day 4 or day 11. (c) TIDCs were harvested 4 or 11 days after tumor inoculation to isolate total RNA.
RT-PCR analysis was performed to assess the levels of IDO1, IDO2, FOXO3, STAT3, and HO-1. All values represent the mean  SE of three to nine mice.
Representative data from two (c) or three (a, b) separate experiments are shown (*P < 0.05 and **P < 0.01). DCs, dendritic cells; FOXO3, forkhead box O3;
HO-1, heme oxygenase-1; IDO1, indoleamine 2,3-dioxygenase 1; IDO2, indoleamine 2,3-dioxygenase 2; LNs, lymph nodes; MFI, mean fluorescence intensity;
PD-L1, programmed death-ligand 1; rDCs, resident DCs; STAT3, signal transducer and activator of transcription 3; TIDCs, tumor-infiltrating dendritic cells;
VEGFR-2, vascular endothelial growth factor receptor 2.
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determining melanoma growth. To compare the capacity for
migration of early and late TIDCs into the draining LNs,
TIDCs labeled with carboxyfluorescein succinimidyl ester
(CFSE) were coinoculated with melanoma cells. CFSEþCD11cþ TIDCs were detected only within the tumor, but not
in draining or nondraining LNs at day 1 or 2 after tumor
inoculation (Supplementary Figure S3 online). These results
indicated that TIDCs remain in place and perform their
function within the tumor microenvironment in this system.Figure 5. Early TIDCs accelerate
tumor growth, whereas late TIDCs
inhibit tumor progression in vivo. (a)
TIDCs were harvested 4 or 11 days
after tumor inoculation. B16
melanoma cells were then injected
intradermally alone or together with
early or late TIDCs. Tumor diameters
were measured approximately every
other day (n ¼ 5 mice for B16 alone
and n ¼ 5 for B16 þ early or late
TIDCs). (b) TIDCs were harvested 4 or
11 days after tumor inoculation. B16
melanoma cells were then cultured
alone or were cocultured with early or
late TIDCs in vitro to assess cell
proliferation. All values represent the
mean  SE. Data are representative of
three independent experiments (*P <
0.05 and **P < 0.01 vs. B16 alone).
TIDCs, tumor-infiltrating dendritic
cells.
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150To explore the direct effects of TIDCs on melanoma cells,
melanoma cells were cocultured with early or late TIDCs
in vitro and cell proliferation was evaluated. However, TIDCs
had no direct effect on cell proliferation (Figure 5b).
Early and late TIDCs modulate the tumor microenvironment
differently
Because TIDCs had no direct effects on melanoma cells, we
next addressed the possibility that they might affect the tumor
microenvironment. Early or late TIDCs were coinjected with
melanoma cells, and mRNA levels of IFN-g, IL-10, IL-6,
transforming growth factor-b, granzyme B, and perforin in
tumors were determined by RT-PCR (Figure 6a). The expres-
sion levels of IFN-g and perforin significantly diminished in
the tumors from the early TIDC group compared with tumors
from the control group. The expression level of granzyme B
was also decreased, but not to a statistically significant level.
As for the other cytokines, there were no significant differ-
ences between the two groups. Because the above results
suggested an insufficient CD8þ T-cell function, we prepared
purified CD8þ T cells from harvested tumors and then
examined the expression of IFN-g, perforin, and granzyme B
using RT-PCR (Figure 6b). The results showed significant
down-regulation of perforin, granzyme B, and IFN-g in the
case of CD8þ T cells isolated from tumors inoculated with
early TIDCs. In sharp contrast, CD8þ T cells isolated from the
late TIDC group showed increased expression of IFN-g,
perforin, and granzyme B (Figure 6c). To confirm the differ-
ential expression of IFN-g at the protein level, we cocultured
the isolated CD8þ T cells with or without B16 melanoma
cells and performed ELISA. CD8þ T cells alone secreted only
small amounts of IFN-g. CD8þ T cells from the control group
could secrete IFN-g in the presence of a B16 tumor. CD8þ T
cells from the late TIDC group secreted significantly larger
amounts of IFN-g than those from the control group in the
presence of B16 cells. However, CD8þ T cells from the early
TIDC group were unable to produce IFN-g in response to
B16 cells (Figure 6d). We assumed that immunoinhibitory
IL-10 secretion might be responsible for the deteriorated
production of IFN-g, but this was not the case. As for IL-10,
CD8þ T cells from all groups could only produce very
small amounts of it (Figure 6d).
DISCUSSION
In this study, we characterized the dynamic function of TIDCs
infiltrating murine melanoma. We found that melanomas are
infiltrated by a significant population of TIDCs, especially at
an early stage of tumor growth, and that TIDCs change their
characteristics drastically during melanoma growth.
Depending on studies, the infiltration of DCs has been
associated with a positive or negative prognostic outcome
(Erdag et al., 2012; Fridman et al., 2011; Jensen et al., 2012;
Ladanyi et al., 2007; Movassagh et al., 2004). This discrep-
ancy can be attributed to differences in the stages of tumor
progression, animal species, as well as the use of markers of
DCs (Garcia-Plata et al., 1995; Simonetti et al., 2007; Vermi
et al., 2003). In the case of mouse studies, evidence now
indicates that TIDCs have diverse roles in the regulation of
murine melanoma growth (Ataera et al., 2011; Diao et al.,
2011; Preynat-Seauve et al., 2006; Stoitzner et al., 2008;Journal of Investigative Dermatology (2016), Volume 136Zhao et al., 2009). These studies imply that the interaction
between melanoma and TIDCs might change during tumor
growth. Our results strongly support the theory. In our study,
the early TIDCs exhibit immunoinhibitory phenotypic and
functional properties, and significantly accelerate melanoma
growth in vivo. On the other hand, the late TIDCs exhibit
completely different phenotypic and functional properties
compared with the early ones, and rather delay melanoma
growth in vivo.
TIDCs are usually thought to capture and process antigens
in the tumor microenvironment and then migrate to draining
LNs, where they may mount an antitumor immune response.
However, effective immune responses and the specific acti-
vation of naive T cells have also been reported directly inside
the tumor (Thompson et al., 2010). Thompson et al. provided
clear evidence that the activation of tumor-specific T cells
takes place in the tumor by TIDCs under conditions where T-
cell migration from the LNs is blocked chemically or in mice
with complete loss of LNs. The present study reiterates the
importance of the tumor microenvironment to foster in-
teractions of TIDCs and T cells.
We then found that the early TIDCs are immunoinhibitory
or insufficient DCs that are incapable of inducing the
immunocompetent maturation of CD8þ T cells, as demon-
strated by the down-regulated expression of IFN-g, perforin,
and granzyme B. In the Matrigel model used in the present
study, the inoculated TIDCs seemed to remain in place and
exert their function within the tumor microenvironment
because the number of migrating TIDCs in the draining LNs
was negligible, whereas TIDCs were detected inside the tu-
mor. This functional change of TIDCs from early immu-
noinhibitory to late immunostimulatory cells was unexpected
because most previous studies reported that various tumors
and their microenvironments evade immune responses by
inhibiting the differentiation or maturation of TIDCs (Liu
et al., 2005). On the other hand, it is also known that
TIDCs have plasticity and retain the capacity to mature into
fully competent antigen-presenting cells. Preynat-Seauve
et al. (2006) reported that TIDCs have an intermediate
maturation phenotype with some expression of costimulatory
molecules. After culture overnight ex vivo, the TIDCs ac-
quired a complete maturation status and were able to activate
and educate naive T cells to eliminate tumor cells (Preynat-
Seauve et al., 2006).
Scarlett et al. (2009) showed the transformation of TIDCs
from immunosuppressive to immunostimulatory cells inside
the tumor. In situ costimulation of CD40 and Toll-like re-
ceptor 3 on TIDCs decreased their L-arginase activity,
enhanced their production of type I IFN and interleukin-12
(p70), augmented their capacity to process antigens, and
upregulated costimulatory molecules and their capacity to
present antigens in vivo in mice (Scarlett et al., 2009). These
studies suggest that TIDCs could become immunostimulatory
mature antigen-presenting cells under some circumstances.
However, the exact mechanisms by which TIDCs are alerted
to the presence of developing melanoma and change their
functions during melanoma growth are not fully understood
at this time.
As was demonstrated previously (Ramirez-Montagut et al.,
2003; Sin et al., 2012), the present study also stresses the
Figure 6. Early and late TIDCs
regulate tumor growth differently by
modulating the tumor
microenvironment and CD8D T-cell
function differently. (a) Tumor tissues
were harvested around day 14 from
each group. Total RNA was isolated
from tumors of mice to analyze gene
expression levels. (b) CD8þ T cells
were purified by magnetic-activated
cell sorting (MACS) to isolate total
RNA. RT-PCR analysis was performed
to assess the levels of IFN-g, granzyme
B, and perforin. CD8þ T cells from
each group were also cocultured with
B16 tumor cells followed by cytokine
measurement using ELISA. All values
represent the mean  SE (n ¼ 3). Data
are representative of three
independent experiments (*P < 0.05
and **P < 0.01 vs. control). TIDCs,
tumor-infiltrating dendritic cells.
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(perforin or granzyme B) in melanoma immunology. In the
melanoma-promoting microenvironment nurtured by early
TIDCs, the expression of IFN-g and perforin is significantlyinhibited. As early TIDCs per se do not directly affect mela-
noma growth, there must be an alternative mechanism. The
insufficient maturation of CD8þ T cells isolated from the
inoculated lesions is evident in terms of the production ofwww.jidonline.org 151
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152IFN-g, perforin, and granzyme B, which is likely to be
attributable to the acceleration of melanoma growth. In this
context, the higher expression of immunoinhibitory mole-
cules such as VEGFR-2 and PD-L1 or immunoinhibitory
genes on early TIDCs is intriguing. Our results coincide with
those obtained by Mimura et al. (2007). They showed that
VEGFR2 ligation by VEGR inhibited the ability of mature DCs
to stimulate allogeneic T cells without affecting CD86 and
MHC class II expression. Peng et al. (2011) reported that
overexpression of PD-L1 in DCs inhibits the proliferation and
IFN-g production of CD8þ T cells. We assume that early
TIDCs possess immunoinhibitory characteristics and prevent
the maturation of immunocompetent CD8þ T cells, leading
to the survival of melanoma cells. There has been an
increasing use of anti-PD-1 therapy, and its efficacy has been
demonstrated in patients treated for metastatic malignant
melanoma. It is currently considered that anti-PD-1 therapy
works on the interaction between effector T cells and tumor
cells. However, our findings suggest that we should consider
not only the interaction between T cells and tumor cells but
also that between DCs and T cells to improve the effects of
such kinds of therapies.
This study has two limitations. Because melanoma growth
is very rapid, we could not investigate the function of TIDCs
at much later stages of tumor growth because of ethical
concerns for the experimental animals. Aggressive mela-
nomas might force the TIDCs to function as immunoinhibi-
tory cells again at a later stage of tumor growth. Another
limitation of our model is that we inject melanoma cells
mixed with Matrigel to harvest tumors at an early stage of
growth. This might have some effects on tumor growth or cell
infiltration into the tumors. However, there are no ideal
naturally occurring murine melanoma models. In addition, it
might be very difficult to identify and harvest early tumors. In
conclusion, our results reveal a dynamic role of TIDCs in
mediating immune reactions against melanoma.
MATERIALS AND METHODS
Mice
C57BL/6J mice (females, 6e8 weeks old) and Balb/c mice (females,
6e8 weeks old) were obtained from Charles River (Japan). The mice
were maintained in a pathogen-free vivarium. All experiments were
approved by the Animal Care and Experiment Committee of Kyushu
University.
Tumor inoculation and isolation of cells infiltrating the
tumor
The B16-F10 murine melanoma cell line (ATCC CRL-6475) was
purchased from the American Type Tissue Culture Collection. After
culture in vivo, B16 cells (3  105) mixed with Matrigel Basement
Membrane Matrix, Growth Factor Reduced (BD Biosciences, San
Jose, CA), were intradermally inoculated into the shaved flanks of
mice. Tumors were removed at various time points after inoculation.
Tumor tissues were digested with 2 mg/ml Collagenase D (Roche,
Basel, Switzerland) and 1 mg/ml DNase I (Sigma-Aldrich, Tauf-
kirchen, Germany) for 1 hour at 37 C, passed through 40 mM filters,
and then tumor-infiltrating cells were isolated by density gradient
centrifugation. In brief, cell pellets were resuspended in 80% Percoll
(GE Healthcare, St Giles, UK), overlaid with 40% Percoll, and the
interface was isolated after 30 minutes of centrifugation at roomJournal of Investigative Dermatology (2016), Volume 136temperature. By using this method, almost all of the tumor-
infiltrating cells were found to be CD45-positive.
Antibodies and flow cytometry
The following fluorochrome-labeled or biotin-conjugated anti-
mouse monoclonal antibodies were obtained from BD Biosciences:
CD11c (HL3), I-Ab (AF6-120.1), and CD86 (GL1). Antibodies to
CD309 (VEGFR2, Avas12a1) were obtained from eBioscience (San
Diego, CA). The antibody to CD274 (PD-L1, 10F.9G2) was obtained
from BioLegend (San Diego, CA). Tumor-infiltrating cells or LN cells
were washed in fluorescence-activated cell sorting (FACS) buffer
(PBS/2% bovine serum albumin/0.1% azide), and 106 cells/ml were
incubated for 10 minutes at 4 C with CD16/CD32 Fc block (BD
Biosciences). Subsequently, the cells were incubated for 30 minutes
at 4 C with the primary antibody or antibodies (1 mg/ml) and
washed twice with FACS buffer. Samples were acquired on FACS-
Canto (Becton Dickinson, Franklin Lakes, NJ) and analyzed with
FlowJo (TreeStar, Ashland, OR).
Isolation of DCs from LNs or tumor
Tissues were minced and digested with collagenase (2 mg/ml;
Roche) and DNase (1 mg/ml; Sigma-Aldrich) at 37 C for 60 min-
utes. Low-density cells were enriched by density centrifugation
(1.083 g/cm3; Nycodenz, Oslo, Norway). The cells or tumor-
infiltrating cells were then purified immunomagnetically by two to
three rounds of positive selection with CD11c (N418) MicroBeads
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to the
manufacturer’s instructions. The purity of DCs was analyzed by FACS
and was between 90% and 94%.
Allogeneic mixed lymphocyte reaction and in vivo cell
proliferation assay
Whole CD3þ T cells were purified with a Pan T Cell Isolation Kit
(Miltenyi Biotec), as instructed by the manufacturer. Various doses of
DCs purified from tumors or LNs were cocultured with 1  105
allogeneic whole T cells from Balb/c mice in triplicate wells of
96-well plates for 4 days. Cell proliferation was then analyzed using
a water-soluble tetrazolium-based colorimetric proliferation assay kit
(Cell Counting Reagent SF; Nacalai Tesque, Kyoto, Japan) according
to the manufacturer’s protocol.
Coinjection model of melanoma cells and isolated TIDCs
After TIDCs had been isolated from the tumors, B16 cells (3  105)
mixed with TIDCs (1  105) were intradermally inoculated into the
shaved flanks of mice. Tumor diameters were measured approxi-
mately every other day, and mice were killed when a tumor ulcer-
ated or reached a maximum diameter of 1 cm, or when they showed
signs of discomfort. In some experiments, TIDCs were labeled with
CFSE before coinjection to assess the localization and migration of
coinjected TIDCs.
Quantitative RT-PCR
Total RNA was isolated from solid tumors or from CD8þ T cells
purified from solid tumors using the Tri-reagent (Invitrogen, Carls-
bad, CA). CD8þ T cells were positively selected using magnetic-
activated cell sorting (Miltenyi). Total RNA was reverse-transcribed
with a first-strand cDNA synthesis kit for RT-PCR (PrimeScript RT
Reagent Kit; Takara Bio), according to the manufacturer’s in-
structions. The reverse-transcribed cDNA was then subjected to
qPCR (SYBR Premix Ex Taq; Takara Bio, Shiga, Japan) and thermal
cycling (Mx3000P Real-Time qPCR Systems; Stratagene, Santa Clara,
CA). The reaction conditions were denaturation at 95 C for 30
seconds, followed by 40 cycles of denaturing at 95 C for 5 seconds,
T Nakahara et al.
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mRNA expression were estimated from the fluorescence intensity
relative to b-actin.
ELISA
CD8þ T cells were cocultured with B16 melanoma cells for 48
hours. IL-10 and IFN-g in each culture supernatant were measured
using cytokine-specific ELISA kits (BioSource, Blue Bell, PA, and
Endogen, Rockford, IL) according to the manufacturers’ protocols.
Statistics
Statistical analysis was performed using SPSS software (version 11.0)
and GraphPad Prism Version 5 (GraphPad Software, La Jolla, CA).
Student’s t-test, Mann-Whitney U test, and two-way ANOVA were
performed to determine the statistical significance of differences. A
P-value < 0.05 is considered significant.
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